Features Of Cytologically Indeterminate Molecularly Benign Nodules Treated With Surgery

Background: Most cytologically indeterminate thyroid nodules (ITNs) with benign molecular testing are not surgically removed.The data on clinical outcomes of these nodules are limited.Methods: We retrospectively analyzed all ITNs where molecular testing was performed either with the Afirma gene expression classifier or Afirma gene sequencing classifier between 2011 and 2018 at a single institution.Results: Thirty-eight out of 289 molecularly benign ITNs were ultimately resected. The most common reason for surgery was compressive symptoms (39%). In multivariable modeling, patients aged <40 years, nodules >= 3 cm, presence of an Afirma suspicious nodule other than the index nodule, and compressive symptoms were associated with higher surgery rates with hazard ratios for surgery of 3.5 (P< 0.001), 3.2 (P< 0.001), 16.8 (P< 0.001), and 7.31 (P< 0.001), respectively. Of resected nodules, 5 were malignant. False-negative rate (FNR) was 1.7%, presuming all unresected nodules were truly benign and 13.2% restricting analysis to resected cases.The FNR was significantly higher in nodules with a high-risk sonographic appearance for cancer (AmericanThyroid Association high-risk classification and American College of Radiology Thyroid Imaging Reporting and Data Systems score of 5) compared with nodules with all other sonographic categories (11.8% vs 1.1%; P- 0.03 and 11.1% vs 1.1%; P= 0.02, respectively).Conclusions: Younger age, larger nodule size, presence of an Afirma suspicious nodule other than the index nodule, and compressive symptoms were associated with a higher rate of surgery. The FNR of benign Afirma was significantly higher in nodules with high-risk sonographic features.